Therapeutic strategy in the initial treatment of Parkinson's disease;Stratégie thérapeutique dans le traitement initial de la maladie de Parkinson

Louvain Medical

Volumn 121, Issue 4, 2002, Pages 93-99

  Mormont, E ^a   Laloux, P ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE; SELEGILINE;

CONFUSION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HALLUCINATION; HUMAN; NAUSEA; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; RESPIRATORY CHAIN; REVIEW; SIDE EFFECT; SOMNOLENCE; VOMITING;

EID: 16844373124     PISSN: 00246956     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. JENNER P., OLANOW C.W. - Oxydative stress and the pathogenesis of Parkinson's disease. Neurology 47 (Suppl 3): S161-S170, 1996.
2. FAHN S. - Is levodopa toxic? Neurology 47 (Suppl 3): S184-S195, 1996.
3. MENA M.A., CASAREJOS M.J., CARAZO A., PAINO C.L., DE YEBENES J.G. - Glia protect fetal midbrain dopamin neurons in culture from L Dopa toxicity through multiple mechanisms. J Neural Transm 104: 317-328, 1997.
4. RAJPUT A.H., FENTON M.E., BIRDI S., MACAULAY R. - Is levodopa toxic to human substantia nigra? Mov Disord 12: 634-638, 1997.
5. QUINN N., PARKES D., JONATA I., MARSDEN C.D. - Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1: 65-68, 1986.
6. JENNER P.G., BRIN M.F. - Levodopa neurotoxicity. Experimental studies versus clinical relevance. Neurology 50 (Suppl 6): S39-S43, 1998.
7. FAHN S. - Parkinson's disease, the effect of levodopa and the ELLDOPA trial. Arch Neurol 56: 529-535, 1999.
8. MARSDEN C.D., PARKS J., QUINN N. - Fluctuation of disability in Parkinson's disease: clinical aspects. In: Mov Disord 92-122, Butter Worth, London, 1992.
9. FERREIRA J.J., RASCOL O. - Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Op Neurol 13: 431-436, 2000.
10. PEARCE R.K., BANERJI T., JENNER P., MARSDEN C.D. - De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset. Mov Disord 13: 234-241, 1998.
11. GERLACH M., YOUDIM M.B.H., RIEDERER P. - Pharmacology of selegiline. Neurology 47 (Suppl 3): S137-S145, 1996.
12. THE PARKINSON STUDY GROUP - Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183, 1993.
13. TETRUD J.W., LANGSTON J.W. - The effect of deprenyl (selegiline) in the natural history of Parkinson's disease. Science 245: 519-522, 1989.
14. MYLLYLÄ V.V., SOTANIEMI K.A., MÄKI-IKOLA O., HEINONEN E.H. - Selegiline as the primary treatment of Parkinson's disease - a long term double blind study. Acta Neurol Scand 95: 211-218, 1997.
15. PALHAGEN S., HEINONEN E.H., HÄGGLUND J., KAUGESAAR T., KONTANTS H., MÄKI-IKOLA O., PALM R., TURUNEN J. and the Swedish Parkinson Study Group - Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51: 520-525, 1998.
16. PRZUNTEK H., CONRAD B., DICHGANS J., KRAUS P.H., KRAUSENECK P., PERGANDE G., RINNE U., SCHIMRICK J., SCHNITKER J., VOGEL H.P. - SELEDO: a 5 year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur J Neurol 6: 141-150, 1999.
17. OLANOW C.W., HAUSER R.A., GAUGER L., MALAPIRA T., KOLLER W. et al. - The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38: 771-777, 1995.
18. LARSEN J.P., BOAS J., ERDAL J.E. and the Norwegian-Danish Study Group - Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. Eur J Neurol 6: 539-547, 1999.
19. MONTASTRUC J.L., RASCOL O., SENARD J.M. - Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 5: 725-730, 1999.
20. YAMAMOTO M. - Do agonists provide neuroprotection? Neurology 51 (Suppl 2): S10-S12, 1998.
21. OLANOW C.W., JENNER P., BROOKS S. - Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44: S167-S174, 1998.
22. IIDA M., MIYAZAKI I., TANAKA K., KABUTO H., IWATA-ICHIKAWA E., OGAWA N. - Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838: 51-59, 1999.
23. ZOU L., JANKOVIC J., ROWE D.B., XIE W., APPEL S.H., LE W. - Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 64: 1275-1285, 1999.
24. RASCOL O., BROOKS D.J., KORCZYN A.D., DE DEYN P.P., CLARKE C.E., LANG A.E. for the 056 Study Group - A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with levodopa or ropinirole. N Engl J Med 342: 1484-1491, 2000.
25. PARKINSON STUDY GROUP - Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 284: 1931-1938, 2000.
26. OERTEL W.H. - Pergolide vs L-dopa (PELMOPET). Mov Disord 15 (Suppl 3): 4, 2000.
27. SHULMAN L.M., MINAGAR A., RABINSTEIN A., WEINER W.J. - The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov Disord 15: 664-668, 2000.
28. FRUCHT S., ROGERS J.D., GREENE P.E., GORDON M.F., FAHN S. - Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908-1910, 1999.
29. OLANOW C.W., WATTS R.L., KOLLER W.C. - An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment Guidelines. Neurology 56: S1-88, 2001.